Lifemin

Lisdexamfetamine dimesylate, the active ingredient in Lifemin, is a Central nervous system stimulant presented as an oral formulation for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults. GNH USA supplies Lifemin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lisdexamfetamine dimesylate is a central nervous system stimulant used in the management of attention deficit hyperactivity disorder (ADHD). - Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in patients diagnosed with ADHD.

Lifemin may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced desire for food, especially in children. - Dry mouth: sensation of oral dryness. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Elevated blood pressure or heart rate: may require medical monitoring. - Psychosis or severe mood changes: emergence of hallucinations or aggressive behavior. - Seizures: rare occurrence of convulsive episodes.

Before prescribing Lifemin, clinicians should evaluate several safety considerations. - Cardiovascular assessment: review history of hypertension, arrhythmia or structural heart disease. - Psychiatric evaluation: assess for prior psychosis, bipolar disorder or severe anxiety. - Substance‑use risk: consider potential for misuse or dependence. - Growth monitoring: regularly track height and weight in pediatric patients. - Concomitant MAO‑inhibitors: avoid use within 14 days of MAOI therapy. - Store at room temperature: keep in the original container, protect from moisture and heat.

Lifemin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Antihypertensive agents: may diminish blood‑pressure‑lowering effect. - Serotonergic drugs (e.g., SSRIs, tramadol): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise plasma levels of active metabolite. - Antacids or acidic foods: can affect absorption rate. - Alcohol: may potentiate central nervous system stimulation.